Hematologic Oncology

Ari Melnick, MD, professor of medicine, Weill Cornell Medical College, discusses the association between epigenetic diversity and clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL).

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the challenges of treating patients with Hodgkin's lymphoma.

Treatment with the oral PI3K-delta inhibitor idelalisib produced an overall response rate of 57% with an average response duration of 12.5 months in heavily pretreated patients with indolent non-Hodgkin's lymphoma.

Harry Erba, MD, PhD, discusses the frequency in which patients with chronic-phase chronic myeloid leukemia (CML) fail to achieve a BCR-ABL transcript level below 10% after 3 months of treatment with imatinib.

Vemurafenib (Zelboraf), a BRAF inhibitor approved to treat melanoma, induced a complete clinical remission in a patient with hairy cell leukemia.

Mark R. Litzow. MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses ways of conducting minimal residual disease (MRD) assessments in patients with acute lymphoblastic leukemia

Adrienne Phillips, MD, MPH, assistant professor of clinical medicine, Columbia University Medical Center, discusses advances in the treatment of HTLV-related adult T-cell leukemia lymphoma.

A crop of targeted agents have demonstrated promising results in fighting chronic lymphocytic leukemia (CLL), suggesting that a range of emerging therapies and drug combinations may be more effective and better tolerated than standard chemotherapy

During his undergraduate years at Princeton University, Charles L. Sawyers, MD, studied history. Now, well into his career as a physician and translational scientist, Sawyers is busy making it.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-targeted T Cells.

The FDA has granted a priority review designation to the intravenous pan-HDAC inhibitor belinostat (Beleodaq) as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma

Genmab, the publicly traded, international biotechnology company, has an oncology pipeline that focuses on two classes of drugs: naked antibodies and antibody drug conjugates

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

Alison J. Moskowitz, MD, is among researchers at Memorial Sloan-Kettering Cancer Center and elsewhere who are investigating an expanded role for the CD30-targeting brentuximab vedotin (Adcetris) in hematologic malignancies. Moskowitz specializes in the treatment of patients with lymphoma and her research focuses on evaluating novel treatments for Hodgkin lymphoma.